While Noctura 400 already has a CE mark, which allows it to be used by patients, it is on a fast track towards approval by NICE (National Institute for Health Care and Excellence) which means it could be available on the NHS within the next two years.
An interview with Richard Kirk – from where it all began to treating 320 million people worldwide.
Richard Kirk, CEO of PolyPhotonix, recently took part in a radio interview to discuss Noctura 400 with Amy Lea at BBC Tees.
PolyPhotonix is on the verge of revolutionising treatment for degenerative sight-threatening conditions caused by age and diabetes.
Makers march to the aid of ailing NHS: fantastic article on PolyPhotonix in The Sunday Times.
PolyPhotonix are on the front page of the The Northern Echo, the front page of the Business section and feature in two other articles in the Business section, including the centre spread.
Competing against hundreds of entries, PolyPhotonix has reached the final shortlist of the UK’s ten most innovative companies.
PolyPhotonix Project Manager, Dr Alison Fisher (right), graduated with a PhD today along with her friends from Durham University.
A new £10m Longitude prize has been launched giving the NHS the opportunity to look for game-changing solutions and answer an array of challenges it currently faces.
Well done to PolyPhotonix Chief Scientist, Alex Cole, who completed the Rock n Roll Liverpool Marathon 2014.